CeD is hallmarked by CD4+ T cells that recognize deamidated gluten epitopes (2), and most of the gluten-specific CD4+ T cells in HLA-DQ2.5+ CeD patients are reactive with the epitopes represented in Nexvax2 (7). Here, CD4 is linked to cranioectodermal dysplasia.